Agios Pharmaceuticals
Agios Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on cellular metabolism therapies for rare diseases. The company discovers and commercializes small molecule medicines targeting metabolic enzymes, including Pyrukynd for pyruvate kinase deficiency and hemolytic anemias. Main revenue drivers comprise commercial sales of Pyrukynd, licensing royalties from biopharmaceutical partners, and milestone development payments. Agios Pharmaceuticals serves hematologists, rare disease medical specialists, academic research hospitals, and patients suffering from rare genetic anemias across North America and Europe. The company holds a market-leading position in cellular metabolism research and pyruvate kinase activator development. Headquartered in Cambridge, Massachusetts, Agios Pharmaceuticals Inc is listed on the Nasdaq Stock Market.
5 of the funds FundTelligence covers report a position in Agios Pharmaceuticals.
- Legal name
- Agios Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
Funds holding Agios Pharmaceuticals
- BNP Health Care Innovators — BNP Paribas · 0.98 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.95 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)